Premier Inc
NASDAQ:PINC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Banaras Beads Ltd
NSE:BANARBEADS
|
IN |
|
I
|
Irm Energy Ltd
NSE:IRMENERGY
|
IN |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (8.1), the stock would be worth $19.14 (10% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 9 | $21.36 |
0%
|
| 3-Year Average | 8.1 | $19.14 |
-10%
|
| 5-Year Average | 9.2 | $21.76 |
+2%
|
| Industry Average | 12.9 | $30.61 |
+43%
|
| Country Average | 14.4 | $34.11 |
+60%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$2.3B
|
/ |
Oct 2025
$255.7m
|
= |
|
|
$2.3B
|
/ |
Jun 2026
$240.6m
|
= |
|
|
$2.3B
|
/ |
Jun 2027
$258.2m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Premier Inc
NASDAQ:PINC
|
1.8B USD | 9 | -53.6 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
98.3B USD | 14.1 | 55.6 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
69.3B EUR | 7.8 | 13.4 | |
| US |
|
Cigna Corp
NYSE:CI
|
72.9B USD | 0 | 12.2 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
24.4B EUR | 9.6 | 18.9 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.2B EUR | 9.1 | 23.8 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
22.6B USD | 12.3 | 22.8 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
22.5B USD | 12.3 | 25.6 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.1B EUR | 5.4 | 11.2 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.8B USD | -31 | -28.4 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.3B USD | 7.1 | 13.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Premier Inc
Glance View
Premier Inc. is a healthcare improvement company that has strategically positioned itself at the intersection of healthcare providers and suppliers, harnessing both data and scale to enhance its value proposition. Born from a collaboration among hospitals to aggregate purchasing power, Premier has evolved into a significant player in transforming healthcare efficiency and efficacy. At its core, the company functions through two primary segments: Supply Chain Services and Performance Services. Within Supply Chain Services, Premier leverages its vast network, which constitutes approximately 4,000 hospitals and health systems, to negotiate group purchasing contracts. This aggregation of demand affords members considerable cost savings, while the company earns a portion of these savings as revenue, combined with fees charged for membership and other related services. Beyond its pioneering roots in group purchasing, Premier also excels in Performance Services, where it delves deeply into analytics, technology, and consulting seamlessly integrated into healthcare operations. By capitalizing on its extensive data repositories, Premier delivers actionable insights that facilitate better decision-making and outcomes for healthcare providers. Through its offerings, such as performance improvement initiatives, technology solutions, and advisory services, Premier helps its members thrive in an increasingly complex healthcare landscape. Ultimately, Premier Inc. sustains its business by creating and capturing value at multiple touchpoints across the healthcare continuum, emphasizing a model that benefits stakeholders by promoting cost reduction, efficiency, and quality improvements.
